Erectile dysfunction and coronary atherothrombosis in diabetic patients: Pathophysiology, clinical features and treatment

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 2, 2006, Pages 173-180

  Gazzaruso, Carmine ^a  

^a IRCCS   (Italy)

Author keywords

Atherosclerosis; Cardiovascular risk; Coronary disease; Diabetes; Endothelial dysfunction; Erectile dysfunction; Phosphodiesterase 5 inhibitors

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LOSARTAN; METFORMIN; NITRATE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VALSARTAN; VARDENAFIL; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

CLINICAL FEATURE; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HUMAN; MALE; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; REVIEW; COITUS; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC ANGIOPATHY; HEART MUSCLE ISCHEMIA; IMPOTENCE; PHYSIOLOGY; RISK FACTOR;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; COITUS; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; IMPOTENCE; MALE; MYOCARDIAL ISCHEMIA; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PRACTICE GUIDELINES; PREVALENCE; RISK FACTORS;

EID: 33646191208     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.2.173     Document Type: Review

References (62)

1. Gazzaruso C. Erectile Dysfunction and silent myocardial ischemia. In: Harrison's Principles of Internal Medicine, 16th Edition Online. DL Kasper (Ed.). McGraw Hill, OH, USA (2005).
2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 84, 50-56 (1999).
3. Feldman HA, Goldstein I, Hatzchristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results from the Massachusetts male aging study. J. Urol. 151, 54-61 (1994).
4. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J. Urol. 163, 788-791 (2000).
5. Fedele D, Bortolotti A, Cosceiii C et al, Gruppo Italiano Studio Deficit Frettile nei Diabetici. Erectile dysfuncion in Type 1 and Type 2 diabetics in Italy. Int. J. Epidemiol. 29, 524-531 (2000).
6. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the 'tip of the iceberg' of a systemic vascular dysorder? Eur. Urol. 44, 352-354 (2003).
7. Cheitlin MD. Should the patient with coronary artery disease use sildenafil? Prev. Cardiol. 6, 161-165 (2003).
8. Montorsi F. Briganti A, Salonia A et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur. Urol. 44, 360-364 (2003).
9. Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial inferction? Results from a retrospective cohort study. Int. J. Impot. Res. 16, 350-353 (2004).
10. Kawanishi Y, Lee KS, Kimura K et al. Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunctional patients. Int. J. Impot. Res. 13, 100-103 (2001).
11. kloner RA, Mullin SH, Shook T et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J. Urol. 170, S46-S50 (2003).
12. Vlachopoulos C, Rokkas K, Ioakeimidis N et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur. Urol. (Epub.) (2005).
13. Chiurlia E, D'Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J. Am. Coll. Cardiol. 46, 1503-1506 (2005).
14. Ponholzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S. Is erectile dysfunction an indicator for increased risk for coronary heart disease and stroke. Eur. Urol. 48, 512-518 (2005)
15. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int. J. Impot. Res. 9, 123-126 (1997).
16. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am. J. Cardiol. 91, 230-231 (2003).
17. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequnet cardiovascular disease. JAMA 294, 2996-3002 (2005)
18. Gazzaruso C, Pujia A, Solerte et al. Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. Int. J. Impot. Res. published online on Oct 13 (2005)
19. Gazzaruso C, Giordanetti S, De Amici E et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 110, 22-26 (2004).
20. Stern S. Symptoms other than chest pain may be important in the diagnosis of 'silent ischemia', or 'the sounds of silence'. Circulation 111, e435-e437 (2005).
21. Ashley EA, Raxval V. Finlay M, Froelicher V. Diagnosing coronary artery disease in diabetic patients. Diabetes Metab. Res. Rev. 18, 201-208 (2002).
22. Solomon H, DeBusk RF. Contemporary management of silent ischemia: the role of ambulatory monitoring. Int. J. Cardiol. 96, 311-319 (2004).
23. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care 21, 1551-1559 (1998).
24. Grundy SM, Cleeman JI, Merz CNB et al, National Cholesterol Education Program. Implications of the recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
25. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction linkes erectile dysfunction to heart disease. Int. J. Clin. Pract. 59, 225-229 (2005).
26. Gazzaruso C. Current opiion on the relationship between athero-thrombosis, type 2 diabetes mellitus and erectile dysfunction. Recenti. Progr. Med. 96, 155-158 (2005).
27. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 26, 1553-1579 (2003).
28. Kaiser DR. Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J. Am. Coll. Cardiol. 43, 179-184 (2004).
29. Yavuzgil O, Altay B, Zoghi M, Gurgun C. Kayikcioglu M, Kultursay H. Endothelial function in patients with vasculogenic erectile dysfunction. Int. J. Cardiol. 103, 19-26 (2005).
30. Bivalacqua TB, Champion HC, Usta MF et al. RhoA/Rho-Kinase suppresses endothelium nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc. Natl Acad. USA 101, 9121-9126 (2004).
31. Sullivan ME, Dashwood MR, Thompson CS, Muddle JR, Mikhailidis DP, Morgan RJ. Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction. J. Urol. 158, 1966-1972 (1997).
32. Francavilla S, Properzi G, Bellini C, Marino G, Ferri C, Santucci A. Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction. J. Urol. 158. 1770-1774 (1997).
33. Endemann DH, Schiffrin EL. Endothelial dysfunction. J. Am. Soc. Nephrol, 15, 1983-1992 (2004).
34. Gnduz MI, Gumus BH, Sekuri C. Relationship between metabolic sindrome and erectile dysfunction. Asian J. Androl. 355-358 (2004).
35. Esposito K, Giugliano F, Martedi E et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care 28, 1201-1203 (2005).
36. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/national Heart. Lung and Blood Institute Scientific Statement. Circulation 112(17), 2735-2752 (2005).
37. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trails. Diabetologia 47, 1914-1923 (2004).
38. Metro MJ, Broderick GA. Diabetes and vascular impotence: does insulin dependence increas the relative severity? Int. J. Impot. Res. 11, 87-89 (1999).
39. Gazzaruso C, Giordanetti S, De Amici E et al. Reply of the authors. Circulation 111, e18-e19 (2005).
40. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM, Development and evaluation of an abridged, 5-item version of the international Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int. J. Impot. Res. 11, 319-326 (1999).
41. Kostis JB, Jackson G, Rosen R et al. Sexual dysfunction and cardiac risk (the second Princeton consensus conference). Am. J. Cardiol. 96, 313-321 (2005).
42. Arruda-Olson AM, Pellikka P. Appropriate use of exercise-testing prior to administration of drugs for treatment of erectile dysfunction. Herz 28, 291-297 (2003).
43. Expert Panel of detection, evaluatoin, and treatment of high blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
44. Cheitlin MD, Hutter A M, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 99, 168-177 (1999).
45. Hermann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in New Engl. J. Med. 342, 1622-1626 (2000).
46. Halcox JPJ, Nour KRA, Zalos G et al. The effect of sildenafil on human vascular function ischemia. J. Am. Coll. Cariol. 40, 1232-1240 (2002).
47. DeBusk RF, Pepine CJ, Glasser DB et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am. J. Cardiol. 93, 147-153 (2004).
48. Fox KM, Thadani U, Ma PT et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur. Heart J. 24, 2206-2212 (2003)
49. Arruda-Olson AM, Mahoney DW, Nehra A et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 287, 719-725 (2002).
50. Thadani U, Smith W, Nash S et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol. 40, 2006-2012 (2002)
51. Kioner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am. J. Cardiol. 92(Suppl.), 37M-46M (2003).
52. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilation in type 2 diabetes. Diabetes Care 25, 1336-1339 (2002).
53. Viachopoulos C, Hirata K, O'Rourke MF. Effect of sildenafil on arterial stiffness and wave reflection. Vasc. Med. 8, 243-248 (2003).
54. Fink HA, MacDonald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction: a systematic review and meta-anaiysis. Arch. Intern. Med. 162, 1349-1360 (2002).
55. Vinik AI, Richardson D. Erectile dysfunction in diabetes. Diabetes Rev. 6, 16-33 (1998).
56. Tan RS, Pu SJ. Impact of obesity on hypogonadism in the andropause. Int. J. Urol. 25, 195-201 (2002).
57. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 56, 302-306 (2000).
58. Esposito K, Giugliano F, Di Palo C et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled study. JAMA 291, 2978-2984 (2004).
59. Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for Therapy. J. Clin. Hypertens. 4, 424-432 (2002).
60. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Preaum (Suppl. 2) 29-34 (2003).
61. Tobili J, Stella I., Nestor Mazza O, Ferder L, Inserra F. Protection of cavernous tissue in male spontaneously hypertensive rats. Beyond blood pressure control. Am. J. Hypertens. 17, 516-522 (2004).
62. Park K, Shin JW, Oh JK, Ryu KS, Kim SW, Paick JS. Restoration of erectile dysfunction capacity in normatensive aged rats by modulation of angiotensin receptor type 1. J. Androl. 26, 123-128 (2005).